Thursday, November 12, 2015
Illumina, a San Diego-based sequencing and array-based technologies provider, has announced that its board of directors has authorized the company to repurchase, on a discretionary basis, up to $250 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The company also announced the completion of the existing discretionary authorization of $96 million that was repurchased since the company reported earnings on Oct. 20.
Illumina has launched the new TruSeq library preparation kits and Infinium arrays that enable researchers to explore genetic variation on a more comprehensive scale. The new additions to the application-driven portfolio address a broad range of genetic studies from whole exome to population and disease specific genotyping, leveraging the Illumina portfolio of genomic analysis systems.
Illumina, a global provider of DNA sequencing and array-based technologies, has joined the Worldwide Innovative Networking (WIN) Consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of academic, industry, insurance and nonprofit research organizations working to make personalized cancer care a reality for patients worldwide.
Memorial Sloan-Kettering Cancer Center (MSK) and Illumina are collaborating to conduct research studies that are critical to understanding the biology of circulating tumor DNA (ctDNA). The studies aim to inform the development of new strategies to diagnose and monitor cancer and to help establish ctDNA as an important marker in the study and eventual treatment of cancer.
Burning Rock, a Guangzhou, China-based diagnostics company, has entered into an agreement to develop advanced clinical applications for molecular diagnostics in oncology based on Illumina’s next-generation sequencing (NGS) technology. The collaboration highlights the importance of genomics to improve healthcare in China.
Illumina, a San Diego-based provider of sequencing and array-based technologies, has signed a definitive agreement to acquire GenoLogics Life Sciences Software, a developer of laboratory information management systems (LIMS) for life sciences organizations. The acquisition strengthens Illumina’s portfolio of genetic analysis solutions.
Illumina, a San Diego-based provider of sequencing and array-based technologies, has launched Illumina SeqLab, an integrated solution for customers with HiSeq X Systems to enable large-scale human whole-genome sequencing operations. Designed to increase laboratory efficiency for population-scale, human whole-genome sequencing (HWGS), this new offering provides a complete solution for Illumina customers who need streamlined workflows with integrated sample tracking and fast and accurate analysis solutions.